Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Tivantinib on the QTC Interval in Cancer Subjects

This study has been completed.
Medpace, Inc.
Information provided by (Responsible Party):
Daiichi Sankyo Inc. Identifier:
First received: October 1, 2012
Last updated: September 30, 2013
Last verified: September 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2013
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)